NMDA subunit 2B-selective negative allosteric modulator satoprodil (BI 1569912) as mono- and adjunctive therapy in patients with major depressive disorder: results from two phase 2 randomized, controlled trials
- DOI
- 10.1038/s41386-026-02538-4
- Published
- 2026-09-05
- Container
- Neuropsychopharmacology
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1038/s41386-026-02538-4,
title = {NMDA subunit 2B-selective negative allosteric modulator satoprodil (BI 1569912) as mono- and adjunctive therapy in patients with major depressive disorder: results from two phase 2 randomized, controlled trials},
author = {Elan A. Cohen and Gerard Sanacora and Koichiro Watanabe and Alla Feldbarg and Rainer-Georg Goeldner and Andreas Scholz and Brittney Starling and Sigurd D. Süssmuth and J. Corey Fowler and Franco De Crescenzo},
year = {2026},
journal = {Neuropsychopharmacology},
doi = {10.1038/s41386-026-02538-4},
url = {https://doi.org/10.1038/s41386-026-02538-4}
}RIS
TY - JOUR TI - NMDA subunit 2B-selective negative allosteric modulator satoprodil (BI 1569912) as mono- and adjunctive therapy in patients with major depressive disorder: results from two phase 2 randomized, controlled trials AU - Elan A. Cohen AU - Gerard Sanacora AU - Koichiro Watanabe AU - Alla Feldbarg AU - Rainer-Georg Goeldner AU - Andreas Scholz AU - Brittney Starling AU - Sigurd D. Süssmuth AU - J. Corey Fowler AU - Franco De Crescenzo PY - 2026 JO - Neuropsychopharmacology DO - 10.1038/s41386-026-02538-4 UR - https://doi.org/10.1038/s41386-026-02538-4 ER -
APA
Cohen, E. A., Sanacora, G., Watanabe, K., Feldbarg, A., Goeldner, R., Scholz, A., Starling, B., Süssmuth, S. D., Fowler, J. C., & Crescenzo, F. D. (2026). NMDA subunit 2B-selective negative allosteric modulator satoprodil (BI 1569912) as mono- and adjunctive therapy in patients with major depressive disorder: results from two phase 2 randomized, controlled trials. Neuropsychopharmacology. https://doi.org/10.1038/s41386-026-02538-4
Source records
- crossref · retrieved 2026-09-26T05:45:58.843Z